RT Journal Article
T1 Editorial: Resistance to Medical Therapy in Pituitary Tumors.
A1 Auriemma, Renata S
A1 Gahete, Manuel D
A1 Gatto, Federico
K1 Adenomas
K1 Dopamine receptors
K1 Pituitary
K1 Resistance
K1 Somatostatin receptors
K1 Tumors
AB Pituitary tumors may exhibit resistance to conventional medical treatments, including somatostatin receptor (SST) ligands (SRLs) and dopamine agonists (DAs) (1, 2). Resistance to medical treatment leads to multi-modal therapies, including surgery and radiotherapy. However, treatment-resistant tumors frequently relapse after radical surgical excision. This is of crucial interest as it occurs in a considerable proportion of patients with pituitary tumors (3). Indeed, resistance to conventional treatments is nowadays considered a predictive factor of the aggressive behavior of the pituitary tumor, being associated with poor prognosis and increased mortality. Predictors of responsiveness to medical treatments are still under investigation, and there is no clear evidence for the best individualized medical therapy in patients with aggressive pituitary lesions
PB Frontiers Research Foundation
SN 1664-2392
YR 2022
FD 2022-01-31
LK http://hdl.handle.net/10668/20561
UL http://hdl.handle.net/10668/20561
LA en
NO Auriemma RS, Gahete MD, Gatto F. Editorial: Resistance to Medical Therapy in Pituitary Tumors. Front Endocrinol (Lausanne). 2022 Feb 23;13:861230
DS RISalud
RD Apr 12, 2025